- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Northera
Synonyms :
droxidopa
Class :
Alpha/beta-agonist
Dosage Forms & Strengths
Capsule, Oral:
100 mg
200 mg
300 mg
100
mg
Orally
3 times a day
increase 100 mg every 48 hours (max. 600 mg 3 times a day)
No safe and efficacious dosing is available
Refer to adult dosing
may enhance the vasopressor effect of alpha-/beta-agonists
may increase the hypertension effect
may have an increased tachycardic effect when combined with Alpha-/Beta-Agonists
may have an increased tachycardic effect when combined with Alpha-/Beta-Agonists
may have an increased tachycardic effect when combined with Alpha-/Beta-Agonists
may have an increased tachycardic effect when combined with Alpha-/Beta-Agonists
may have an increased tachycardic effect when combined with Alpha-/Beta-Agonists
may have an increased hypertensive effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may have an increased tachycardic effect when combined with alpha-/beta-agonists
may increase the vasoconstricting effect of hyaluronidase
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect
it increases the effect of hypertension of alpha 1-agonists
it increases the effect of hypertension of alpha 1-agonists
it increases the effect of hypertension of alpha 1-agonists
it increases the effect of hypertension of alpha 1-agonists
it increases the effect of hypertension of alpha 1-agonists
it increases the effect of hypertension of alpha 1-agonists
alpha-1 agonists decrease the efficacy of other alpha-1 agonists
alpha-1 agonists decrease the efficacy of other alpha-1 agonists
alpha-1 agonists decrease the efficacy of other alpha-1 agonists
alpha-1 agonists decrease the efficacy of other alpha-1 agonists
alpha-1 agonists decrease the efficacy of other alpha-1 agonists
they increase the effect of vasoconstriction of alpha-1 agonists
they increase the effect of vasoconstriction of alpha-1 agonists
they increase the effect of vasoconstriction of alpha-1 agonists
they increase the effect of vasoconstriction of alpha-1 agonists
they increase the effect of vasoconstriction of alpha-1 agonists
may increase the hypertension effect
may increase the toxic effect of beta2 agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may have an increased vasoconstricting effect when combined with alpha1-agonists
may decrease the therapeutic effect when combined with iobenguane products
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with alpha1-agonists
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may increase the hypertensive effect
may have an increased vasoconstricting effect when combined with alpha-/beta-agonists
Carbonic Anhydrase Inhibitors may increase the levels of serum concentration of Alpha-/Beta-Agonists
Carbonic Anhydrase Inhibitors may increase the levels of serum concentration of Alpha-/Beta-Agonists
Carbonic Anhydrase Inhibitors may increase the levels of serum concentration of Alpha-/Beta-Agonists
Carbonic Anhydrase Inhibitors may increase the levels of serum concentration of Alpha-/Beta-Agonists
Carbonic Anhydrase Inhibitors may increase the levels of serum concentration of Alpha-/Beta-Agonists
alpha1-Blockers may reduce the vasoconstricting effect of alpha-/Beta-agonist
bunazosin (Not available in the United States)
alpha1-Blockers may reduce the vasoconstricting effect of alpha-/Beta-agonist
alpha1-Blockers may reduce the vasoconstricting effect of alpha-/Beta-agonist
alpha1-Blockers may reduce the vasoconstricting effect of alpha-/Beta-agonist
alpha1-Blockers may reduce the vasoconstricting effect of alpha-/Beta-agonist
carbonic anhydrase inhibitors may enhance the levels of serum concentration of alpha-/beta-agonists
carbonic anhydrase inhibitors may enhance the levels of serum concentration of alpha-/beta-agonists
carbonic anhydrase inhibitors may enhance the levels of serum concentration of alpha-/beta-agonists
carbonic anhydrase inhibitors may enhance the levels of serum concentration of alpha-/beta-agonists
carbonic anhydrase inhibitors may enhance the levels of serum concentration of alpha-/beta-agonists
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may have an increased hypertensive effect when combined with droxidopa
may have an increased hypertensive effect when combined with droxidopa
may have an increased hypertensive effect when combined with droxidopa
may have an increased hypertensive effect when combined with droxidopa
may have an increased hypertensive effect when combined with droxidopa
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
may increase the levels of serum concentration of alpha-/beta-agonists
may increase the levels of serum concentration of alpha-/beta-agonists
may increase the levels of serum concentration of alpha-/beta-agonists
may increase the levels of serum concentration of alpha-/beta-agonists
may increase the levels of serum concentration of alpha-/beta-agonists
they increase the efficacy of alpha 1-agonists
it increases the effect of hypertension of alpha-1 agonists
may decrease the vasoconstriction effects
bunazosin (Not available in the United States)
may decrease the vasoconstriction effects
may decrease the vasoconstriction effects
may decrease the vasoconstriction effects
may decrease the vasoconstriction effects
may increase the hypertensive effect of Serotonin 5-HT1D Receptor Agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may decrease the vasoconstricting effect when combined with alpha1-agonists
may have an increased hypertensive effect when combined with droxidopa
May increase the levels of serum concentration
May increase the levels of serum concentration
May increase the levels of serum concentration
May increase the levels of serum concentration
May increase the levels of serum concentration
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may increase the vasopressor effect
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may have an increased hypertensive effect when combined with alpha-/beta-agonists
may have an increased hypertensive effect when combined with alpha-/beta-agonists
may decrease the vasoconstricting effect when combined with alpha-/beta-agonists
may have an increased hypertensive effect when combined with vasopressin
It may enhance the serum concentration when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
It may enhance the serum concentration when combined with alkalinizing agents
may enhance the serum concentration when combined with alpha-/beta-agonists
may enhance the serum concentration when combined with alpha-/beta-agonists
may enhance the serum concentration when combined with alpha-/beta-agonists
may enhance the serum concentration when combined with alpha-/beta-agonists
may enhance the serum concentration when combined with alpha-/beta-agonists
Frequency defined:
>10%
Headache
1% to 10%
Hypertension
Nausea
Dizziness
Postmarketing
Chest pain
Abdominal pain
Diarrhea
Pancreatitis
Vomiting
Behavioral changes
Blurred vision
hallucinations
Pregnancy consideration: Few adverse effects were reported in animal reproductive studies. Contradicted for pregnant women.
Lactation: excretion of droxidopa in breast milk is not known.
Pregnancy category:
Patient information leaflet
Generic Name: Droxidopa
Pronounced: droxidopa
Why do we use droxidopa?
Droxidopa is used for the treatment of hypotension.